BACKGROUND AND PURPOSE: Protease-activated receptor 1 (PAR1) has been demonstrated to be involved in the pathogenesis of viral diseases. However, its role remains controversial. The goal of our study was to investigate the contribution of PAR1 to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. EXPERIMENTAL APPROACH: Pharmacological approaches were used to investigate the role of PAR1 during RSV and hMPV infection, in vitro using epithelial A549 cells and in vivo using a mouse model of virus infection. KEY RESULTS: In vitro, the PAR1 antagonist RWJ-56110 reduced the replication of RSV and hMPV in A549 cells. In agreement with these results, RWJ-56110-treated mice were protected against RSV and hMPV infections, as indicated by less weight loss and mortality. This protective effect in mice correlated with decreased lung viral replication and inflammation. In contrast, hMPV-infected mice treated with the PAR1 agonist TFLLR-NH2 showed increased mortality, as compared to infected mice, which were left untreated. Thrombin generation was shown to occur downstream of PAR1 activation in infected mice via tissue factor exposure as part of the inflammatory response, and thrombin inhibition by argatroban reduced the pathogenicity of the infection with no additive effect to that induced by PAR1 inhibition. CONCLUSION AND IMPLICATIONS: These data show that PAR1 plays a detrimental role during RSV and hMPV infections in mice via, at least, a thrombin-dependent mechanism. Thus, the use of PAR1 antagonists and thrombin inhibitors may have potential as a novel approach for the treatment of RSV and hMPV infections.
BACKGROUND AND PURPOSE:Protease-activated receptor 1 (PAR1) has been demonstrated to be involved in the pathogenesis of viral diseases. However, its role remains controversial. The goal of our study was to investigate the contribution of PAR1 to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. EXPERIMENTAL APPROACH: Pharmacological approaches were used to investigate the role of PAR1 during RSV and hMPVinfection, in vitro using epithelial A549 cells and in vivo using a mouse model of virus infection. KEY RESULTS: In vitro, the PAR1 antagonist RWJ-56110 reduced the replication of RSV and hMPV in A549 cells. In agreement with these results, RWJ-56110-treated mice were protected against RSV and hMPV infections, as indicated by less weight loss and mortality. This protective effect in mice correlated with decreased lung viral replication and inflammation. In contrast, hMPV-infectedmice treated with the PAR1 agonist TFLLR-NH2 showed increased mortality, as compared to infected mice, which were left untreated. Thrombin generation was shown to occur downstream of PAR1 activation in infected mice via tissue factor exposure as part of the inflammatory response, and thrombin inhibition by argatroban reduced the pathogenicity of the infection with no additive effect to that induced by PAR1 inhibition. CONCLUSION AND IMPLICATIONS: These data show that PAR1 plays a detrimental role during RSV and hMPV infections in mice via, at least, a thrombin-dependent mechanism. Thus, the use of PAR1 antagonists and thrombin inhibitors may have potential as a novel approach for the treatment of RSV and hMPV infections.
Authors: P Andrade-Gordon; B E Maryanoff; C K Derian; H C Zhang; M F Addo; A L Darrow; A J Eckardt; W J Hoekstra; D F McComsey; D Oksenberg; E E Reynolds; R J Santulli; R M Scarborough; C E Smith; K B White Journal: Proc Natl Acad Sci U S A Date: 1999-10-26 Impact factor: 11.205
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: Janet L K Wee; Yok-Teng Chionh; Garrett Z Ng; Stacey N Harbour; Cody Allison; Charles N Pagel; Eleanor J Mackie; Hazel M Mitchell; Richard L Ferrero; Philip Sutton Journal: Gastroenterology Date: 2009-08-23 Impact factor: 22.682
Authors: Julie A Bastarache; Richard D Fremont; Jonathan A Kropski; Frederick R Bossert; Lorraine B Ware Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-08-21 Impact factor: 5.464
Authors: Silvio Antoniak; A Phillip Owens; Martin Baunacke; Julie C Williams; Rebecca D Lee; Alice Weithäuser; Patricia A Sheridan; Ronny Malz; James P Luyendyk; Denise A Esserman; JoAnn Trejo; Daniel Kirchhofer; Burns C Blaxall; Rafal Pawlinski; Melinda A Beck; Ursula Rauch; Nigel Mackman Journal: J Clin Invest Date: 2013-02-08 Impact factor: 14.808
Authors: Ha Neui Kim; Erin M Triplet; Maja Radulovic; Samantha Bouchal; Laurel S Kleppe; Whitney L Simon; Hyesook Yoon; Isobel A Scarisbrick Journal: Glia Date: 2021-04-22 Impact factor: 8.073
Authors: Hui Chen; Mindy Smith; Jasmin Herz; Tong Li; Rebecca Hasley; Cecile Le Saout; Ziang Zhu; Jie Cheng; Andres Gronda; José A Martina; Pablo M Irusta; Tatiana Karpova; Dorian B McGavern; Marta Catalfamo Journal: iScience Date: 2021-10-30
Authors: Nicolás M S Gálvez; Catalina A Andrade; Gaspar A Pacheco; Jorge A Soto; Vicente Stranger; Thomas Rivera; Abel E Vásquez; Alexis M Kalergis Journal: Viruses Date: 2021-03-22 Impact factor: 5.048